Lyophilization USA Conference 2017

SMi Group16 - 17 November 2017, Iselin, USA.
As biopharmaceuticals continue to dominate the market the need for greater shelf life and protein stability has increased. For many biological products lyophilization is a necessity and the technology is constantly advancing. As manufacturing demands increase the global lyophilization market for pharmaceutical and biotechnology products is expected to reach $2.66 billion by 2019 and this a trend that is likely to continue as we push the boundaries of biopharmaceutical formulation and transport.

One of the main challenges in pharmaceutical lyophilization continues to be the scale- up and the implementation of QbD protocols for the optimization of cycles. Several companies are researching and developing ways to facilitate commercial bulk lyophilisation of vaccines, protein and cells while also reducing costs.

Lyophilization USA will gather leading experts from top pharma companies to discuss the latest cutting-edge developments in freeze drying, as well as solutions to on-going industry challenges.

Key Topics Addressed:

  • The impact of controlled nucleation on product quality and the technology being used for controlled ice nucleation.
  • Examining the development and scale up of a freeze-drying cycle for biotherapeutics.
  • Highlighting the approaches to effective holistic packaging and innovative design.

Featured Speakers:

  • Lokesh Kumar, Associated Scientist, Genentech
  • Charlie Tang, Associate Director, Formulation Development, Regeneron Pharmaceuticals
  • Guido Schmitz, Global Head of Packaging & Technology Innovation, Bayer Consumer Care
  • Perceval Sondag, Principal Statistician, Arlenda
  • Eric Munson, Professor, Pharmaceutical Sciences, University of Kentucky
  • Kelly Forney Stevens, Drug Product Development, GSK Vaccines
  • Melissa Lash, Scientist, Large Molecule Drug Development, Johnson & Johnson

For further information and to register, please visit:
http://www.smi-online.co.uk/pharmaceuticals/northamerica/Lyophilisation-USA

About SMi Group
The SMi Group is a highly Professional, Independent and Global company that specialises in the production of Business-to-Business Conferences, Workshops and Masterclasses. We research, create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical sectors.

We believe in bringing you the best events incorporating:

  • In-depth analysis of the subject matter
  • Tools, techniques and information to immediately benefit your business
  • High level contact with expert speakers
  • Insight into new areas, refreshing your knowledge
  • Opportunities to learn from key opinion leaders, and to engage through Q&A
  • Sessions with leading professionals and to network before, during and after event

Our management team has more than 70 years collective experience in the conference industry and our long-term success has been established by providing a reliable and expert service. This gives you the delegate, the confidence and reassurance, in knowing that we have brought you the best speakers and content for 20 years. The SMi management team plays a very active role in the day to day running of the business and events and we look forward to meeting you at an event soon!

Most Popular Now

Pfizer and BioNTech complete submission to Europea…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the European Medicines Agency (EMA) for an Omicron-adapted biva...

Lilly will supply an additional 150,000 doses of b…

Eli Lilly and Company (NYSE: LLY) announced a modified purchase agreement with the U.S. government to supply an additional 150,000 doses of bebtelovimab for approximately...

Bayer to sell men's health product Nebido™ to Grün…

Bayer and Grünenthal have entered into a definitive agreement regarding the sale of Bayer's men's health product Nebido™ (testosterone undecanoate), for a purchase price ...

AstraZeneca to acquire TeneoTwo and its clinical-s…

AstraZeneca announced an agreement to acquire TeneoTwo, Inc. (TeneoTwo)i, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluatio...

Demonstration of a potent, universal coronavirus m…

The SARS-CoV-2 that causes COVID-19 has killed 6.3 million people worldwide since 2019, painfully highlighting the vulnerability of humanity to novel coronaviruses. Re...

The fourth COVID-19 vaccine reduces the risk of de…

A new study by Tel Aviv University and Ben Gurion University of the Negev, in collaboration with the Israeli Ministry of Health, has found that the fourth COVID-19 vaccin...

Vaccine protection against COVID-19 short-lived, b…

Since COVID-19 vaccines first became available to protect against infection and severe illness, there has been much uncertainty about how long the protection lasts, and w...

Research shows investigational drug fosters nerve …

Scientists from the University of Birmingham have shown that a brain-penetrating candidate drug currently in development as a cancer therapy can foster regeneration of da...

NIH launches clinical trial of mRNA Nipah virus va…

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has launched an early-stage clinical trial evaluating an inv...

Anti-inflammatory compound shows potential in trea…

An anti-inflammatory compound may have the potential to treat systemic inflammation and brain injury in patients with severe COVID-19 and significantly reduce their chanc...

Vaccine-induced immune response to omicron wanes s…

Although COVID-19 booster vaccinations in adults elicit high levels of neutralizing antibodies against the Omicron variant of SARS-CoV-2, antibody levels decrease substan...

SARS-CoV-2 hijacks nanotubes between neurons to in…

COVID-19 often leads to neurological symptoms, such as a loss of taste or smell, or cognitive impairments (including memory loss and concentration difficulties), both dur...